Secukinumab therapy for moderate to severe plaque psoriasis is associated with high rates of long-term retention and sustained efficacy, real-world patient data show.

Results from the longitudinal European SERENA study — funded by secukinumab sponsor Novartis — show that nearly two-thirds of patients persist with the monoclonal antibody for up to three years, with minimal impact from treatment interruption.

The German-led researchers say their findings were reassuring and indicative of “high treatment persistence” in routine clinical practice.

The team analysed data from 1756 adults (average age 48) with moderate to severe plaque psoriasis who had received more than 16 weeks of secukinumab therapy before enrolment and were followed for two or more years.